Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 15,949,282 shares, an increase of 24.4% from the December 15th total of 12,819,308 shares. Based on an average trading volume of 5,642,145 shares, the short-interest ratio is presently 2.8 days. Approximately 10.7% of the shares of the company are short sold. Approximately 10.7% of the shares of the company are short sold. Based on an average trading volume of 5,642,145 shares, the short-interest ratio is presently 2.8 days.

Analyst Upgrades and Downgrades

PALI has been the subject of a number of analyst reports. B. Riley assumed coverage on Palisade Bio in a research report on Friday, January 9th. They set a “buy” rating and a $7.00 price objective for the company. Piper Sandler assumed coverage on shares of Palisade Bio in a report on Monday, December 29th. They set an “overweight” rating and a $25.00 price target for the company. Clear Str raised shares of Palisade Bio to a “strong-buy” rating in a report on Monday, December 29th. Citigroup reissued a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Finally, Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Palisade Bio Stock Up 9.3%

Palisade Bio stock traded up $0.16 during trading hours on Tuesday, hitting $1.82. 3,598,377 shares of the company traded hands, compared to its average volume of 5,915,073. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.64. The firm has a market cap of $270.44 million, a P/E ratio of -0.86 and a beta of 1.43. The firm’s 50-day simple moving average is $2.02 and its two-hundred day simple moving average is $1.42.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.06). On average, equities research analysts predict that Palisade Bio will post -12.43 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.